NCT03278938

Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

Add-on to Cognitive, ERP and EEG Asymmetry in Affective Disorders (#6559R) [Formerly #5723]

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: New York State Psychiatric Institute · Academic / Other
• Sex: All
• Age: 18 Years – 66 Years
• Healthy volunteers: Not accepted

Summary

Depressed patients unremitted after monotherapy with citalopram or bupropion will remit following six weeks treatment with the combination of citalopram and bupropion.

Detailed description

Participants in another study who did not remit during 12 weeks treatment with citalopram (to 40 mg/d) or bupropion (to 450 mg/d) will have citalopram (to 40 mg/d) or bupropion (to 450 mg/d) added for six weeks.

Conditions

• Depressive Illness

Interventions

Type	Name	Description
DRUG	bupropion	FDA approved drug for treating depression
DRUG	citalopram	FDA approved treatment for depression

Timeline

• Start date: 2012-06-29
• Primary completion: 2016-01-01
• Completion: 2016-01-01
• First posted: 2017-09-12
• Last updated: 2019-03-15

Locations

1 site across 1 country: United States